Hiltonol injection for prostate cancer on active surveillance
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a drug called Hiltonol (Poly-ICLC) given directly into the prostate tumor along with an injection under the skin. It is for men with low-risk prostate cancer who are on active surveillance, to see if the drug can slow or stop the cancer from growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have low-grade prostate cancer (Gleason 3+3 or 3+4) and be a candidate for active surveillance.
- You must be willing to have an injection of the study drug directly into your prostate tumor.
- You must not have had any prior cancer treatment for prostate cancer (like surgery, radiation, or hormone therapy).
- You must not have active infections or conditions that increase the risk of infection from the injection.
- You must have adequate kidney, liver, and blood cell function as shown by lab tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new imaging test called rhPSMA-7.3 (18F) PET/CT to see if it can better detect prostate cancer in men who are on active surveillance because their cancer is considered low-risk or favorable intermediate-risk. You would also get an MRI and a biopsy as part of the study.
This Phase 1 trial tests a small-molecule treatment that carries radioactive material to help treat prostate cancer that has spread and keeps growing despite standard hormone-blocking treatment. It’s mainly looking to find a safe dose and see how well the approach works in people with limited treatment options.
This study tests a new diagnostic drug called HRS-1738 to see if it can help detect prostate cancer more clearly on PET/CT scans. If you have prostate cancer that has been confirmed by a biopsy and you are in fairly good health, this trial may help improve how your cancer is seen and monitored.
This trial tests a new vaccine (TriAdeno) combined with an immune-boosting drug to help your body fight early-stage prostate cancer while you're on active surveillance—a watchful waiting approach. The vaccine may help prevent cancer growth without surgery or radiation.
This trial tests a radioactive drug called Lu 177 JH020002 for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. The drug targets a protein on cancer cells to deliver radiation directly, possibly slowing the disease.
This study tests whether testosterone replacement therapy can safely improve low testosterone symptoms in men with low-risk prostate cancer who are not receiving active treatment. You may be eligible if you have confirmed low testosterone and are being monitored without intervention.
Hear when a new Prostate Cancer Patients on Active Surveillance trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.